IL-24’s ability to block proliferation and decrease the stemness of osteosarcoma CSCs was initially tested in in vitro cultured cells and was subsequently translated into an in vivo pre-clinical model by using a nude mouse xenograft. Here, IL24 is linked to osteosarcoma.